Aktis Oncology, Inc. (AKTS) Q3 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good day, ladies and gentlemen, and welcome to the Acoustis Technologies fiscal 2024 third quarter conference call. As a reminder, this conference is being recorded. At the conclusion of the company presentation, Acoustis management will take questions. To ask a question, please press star 1 on your telephone keypad to be placed into the queue. A replay of the call will be available on the investor relations section of the Acoustis website. Thank you. Thank you, Operator, and good morning to everyone on the call. Welcome to Acousis' third quarter fiscal 2024 conference call. I am Ken Bowler, CFO, and I'm joined today by our founder and CEO, Jeff Shealy, Corporate General Counsel, Drew Wright, and EDP of Business Development, Dave Eichle. Before we begin, please note that today's presentation includes forward-looking statements about our business outlook. All statements other than statements of historical facts included in this conference call, such as expectations regarding our strategies and operations, including the timing and prospects of product development and customer orders and design wins, possible collaborative or partnering relationships, litigation matters, and expected financial and operating results, are forward-looking statements. Such forward-looking statements are predictions based on the company's expectations as of today. and are subject to numerous risks and uncertainties. The company and our management team assume no obligation to update any forward-looking statements made on today's call. Our SEC filings mention important factors that could cause actual results to differ materially. Please refer to our latest Form 10-K and Form 10-Q filed with the SEC to get a better understanding of those risks and uncertainties. In addition, our presentation to...